{ "items": [ "\n\n
\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Clinical trials\n \n \n \n \n Infection, Respiratory and Acute Care\n \n \n\n \n\n\n
\n \n\n \n23 June 2021
\n \n \n \nFrom today, ivermectin is being investigated in the UK as part of the Platform Randomised Trial of Treatments in the Community for Epidemic and Pandemic Illnesses (PRINCIPLE), the world\u2019s largest clinical trial of possible COVID-19 treatments for recovery at home and in other non-hospital settings.
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Clinical trials\n \n \n\n \n\n\n
\n \n\n \n20 May 2021
\n \n \n \nEach year, International Clinical Trials Day recognises the people who conduct clinical trials, giving our community a chance to say thank you for everything they do to improve public health. This year our trials unit staff are sharing what makes them proud to be part of Oxford\u2019s Primary Care Clinical Trials Unit.
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Clinical trials\n \n \n \n \n Infection, Respiratory and Acute Care\n \n \n\n \n\n\n
\n \n\n \n12 April 2021
\n \n \n \nInhaled budesonide, a common corticosteroid, is the world's first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants. As of today, the treatment is available in UK primary care on a case-by-case basis.
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Clinical trials\n \n \n \n \n Infection, Respiratory and Acute Care\n \n \n\n \n\n\n
\n \n\n \n8 April 2021
\n \n \n \nCould the antiviral favipiravir help transform COVID-19 into an illness that can be successfully treated by general practitioners?
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Clinical trials\n \n \n \n \n Infection, Respiratory and Acute Care\n \n \n\n \n\n\n
\n \n\n \n3 March 2021
\n \n \n \nFrom today, the UK\u2019s national priority platform trial of Covid-19 treatments for recovery at home launches its investigation of the gout drug colchicine, and expands for the first time to include adults of any age.
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Clinical trials\n \n \n \n \n Infection, Respiratory and Acute Care\n \n \n\n \n\n\n
\n \n\n \n25 January 2021
\n \n \n \nUpdate from the Chief Investigators of the Platform Randomised trial of INterventions against COVID-19 In older peoPLE (PRINCIPLE), 25 January 2021
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Clinical trials\n \n \n \n \n Infection, Respiratory and Acute Care\n \n \n\n \n\n\n
\n \n\n \n27 November 2020
\n \n \n \nIn Covid-19, inhaled budesonide may prevent damaging inflammation, stop the virus from getting into lung cells and inhibit viral replication.
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Clinical trials\n \n \n\n \n\n\n
\n \n\n \n18 November 2020
\n \n \n \nTwo of the UK\u2019s largest pharmacy chains, LloydsPharmacy and Well Pharmacy, are tasking their branches with helping to find suitable patients for the PRINCIPLE Trial of Covid-19 treatments.
\n \n\n \n \n\n \n\n \n \n \n \n Awards & appointments\n \n \n \n \n Clinical trials\n \n \n \n \n Infection, Respiratory and Acute Care\n \n \n\n \n\n\n
\n \n\n \n23 October 2020
\n \n \n \nThe importance of patient and public contributors is recognised as key to the success of the study.
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Clinical trials\n \n \n \n \n Infection, Respiratory and Acute Care\n \n \n\n \n\n\n
\n \n\n \n21 October 2020
\n \n \n \nEurope\u2019s BAPS Swaminarayan Sanstha, the largest Hindu temple outside of India, is supporting their community during the coronavirus pandemic by spreading awareness of the PRINCIPLE trial of Covid-19 treatments.
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Clinical trials\n \n \n \n \n Infection, Respiratory and Acute Care\n \n \n\n \n\n\n
\n \n\n \n1 October 2020
\n \n \n \nMore than 1000 people across the UK have signed-up to take part in the UK-wide PRINCIPLE Trial of potential community-based treatments for COVID-19, led by Oxford University.
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Clinical trials\n \n \n\n \n\n\n
\n \n\n \n18 September 2020
\n \n \n \nProfessor Mahendra G Patel, University of Bradford, joins PRINCIPLE Trial as National Black, Asian and minority ethnic Community and Pharmacy Lead
\n \n\n \n \n\n \n\n \n \n \n \n Clinical trials\n \n \n \n \n Infection, Respiratory and Acute Care\n \n \n\n \n\n\n
\n \n\n \n7 July 2020
\n \n \n \nThere is no evidence to suggest a daily combination of probiotics reduces the need for antibiotics to treat acute infections in care home residents, finds a study led by Oxford University researchers published in JAMA.
\n \n\n \n \n\n \n\n \n \n \n \n Cardiovascular & metabolic\n \n \n \n \n Clinical trials\n \n \n\n \n\n\n
\n \n\n \n26 May 2020
\n \n \n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Clinical trials\n \n \n \n \n Infection, Respiratory and Acute Care\n \n \n\n \n\n\n
\n \n\n \n12 May 2020
\n \n \n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Clinical trials\n \n \n \n \n Global perspective\n \n \n \n \n Infection, Respiratory and Acute Care\n \n \n\n \n\n\n
\n \n\n \n17 April 2020
\n \n \n \nResearchers from Oxford University are now enrolling participants into the first clinical trial of potential COVID-19 treatments to take place in GP practices.
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Clinical trials\n \n \n \n \n Infection, Respiratory and Acute Care\n \n \n\n \n\n\n
\n \n\n \n30 March 2020
\n \n \n \nThe Nuffield Department of Primary Care Health Sciences at the University of Oxford and the Royal College of General Practitioners (RCGP) have joined forces with clinical system supplier EMIS Health to urgently recruit as many GP practices as possible for COVID-19 research.
\n \n\n \n \n\n \n\n \n \n \n \n Cardiovascular & metabolic\n \n \n \n \n Clinical trials\n \n \n\n \n\n\n
\n \n\n \n11 February 2020
\n \n \n \nMore than 18 percent of over 60's have chronic kidney disease (CKD), around 44 percent of whom are undiagnosed without screening, finds a study led by Oxford University researchers.
\n \n\n \n \n\n \n\n \n \n \n \n Clinical trials\n \n \n \n \n Infection, Respiratory and Acute Care\n \n \n\n \n\n\n
\n \n\n \n12 December 2019
\n \n \n \nA Europe-wide study conducted over three flu seasons finds that the antiviral drug, oseltamivir (Tamiflu\u00ae), can help people recover from flu-like illness about one-day sooner on average, with older, sicker patients who have been unwell for longer recovering two-to-three days sooner.
\n \n\n \n \n\n \n\n \n \n \n \n Awards & appointments\n \n \n \n \n Clinical trials\n \n \n \n \n Infection, Respiratory and Acute Care\n \n \n\n \n\n\n
\n \n\n \n4 December 2019
\n \n \n \n\n \n \n